Kane Biotech (CVE:KNE) Shares Down 4.5% – Time to Sell?

Kane Biotech Inc. (CVE:KNE) traded down 4.5% during mid-day trading on Tuesday . The stock traded as low as C$0.10 and last traded at C$0.11. 186,000 shares traded hands during mid-day trading, an increase of 145% from the average session volume of 76,044 shares. The stock had previously closed at C$0.11.

Kane Biotech Stock Performance

The company has a current ratio of 0.80, a quick ratio of 0.39 and a debt-to-equity ratio of -331.42. The firm has a 50-day moving average of C$0.11 and a 200-day moving average of C$0.12. The stock has a market capitalization of C$15.13 million, a price-to-earnings ratio of 2.63 and a beta of 0.52.

Insider Activity at Kane Biotech

In other Kane Biotech news, Director Marc Edwards purchased 2,000,000 shares of the stock in a transaction on Friday, January 17th. The shares were bought at an average cost of C$0.10 per share, with a total value of C$200,000.00. 37.21% of the stock is owned by insiders.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.